Pfizer's Xeljanz is an obvious beneficiary of Eli Lilly's surprise Olumiant (baricitinib) rejection at the FDA. But AbbVie and Gilead could gain, too.

Pharma has come a long way on patient centricity. Regulators, though? Not so much, Treato's CEO says.

While some analysts aren’t thrilled by Allergan's phase 2 data for Botox in depression, the company sees enough promise to move the therapy into a wide…

Mylan faces a class action lawsuit over its pricing of allergy shot EpiPen—the first suit alleging the company violated the federal RICO Act.

A top Senate Democrat is throwing the weight of her office behind efforts to dig into opioid marketing practices.

The new multiple sclerosis med Roche has been anticipating—and the market shake-up other drugmakers have been dreading—is here.

Even as Pfizer’s vaccine outfit suffers a painful Prevnar 13 slowdown around the world, the group may soon get a boost in Europe.

Hot on the heels of Tesaro's FDA nod for Zejula in ovarian cancer, AstraZeneca has nabbed priority review for its med Lynparza in the same treatment…

After a failed serelaxin trial, Novartis has to tear up sales estimates it hinted at in January, leaving Entresto to carry the load in heart failure—if it can…